Hadassah

Placental Stem Cell Therapy Saves Hadassah Patient with Bone Marrow Failure

Wednesday, Aug 8 2012

A woman with terminal bone marrow failure was saved at the Hadassah Medical Center with placental stem cell therapy, marking the second successful treatment of a patient with this life-threatening medical condition in three months.

This most recent case involved a woman who had lymphoma and failed to respond to both chemotherapy and bone marrow transplants. When Pluristem Therapeutics' PLX cells were injected intramuscularly, her clinical condition and blood count improved---so much so that she has been released from the hospital.

Before the woman received the PLX cells, her red and white blood cell counts were low and she was highly susceptible to infections. "This is a real breakthrough," said Prof. Reuven Or, Director of Bone Marrow Transplantation and Cancer Immunology at Hadassah. When the autologous bone marrow transplants engrafted poorly, he related, "as a last resort," they applied to treat her with PLX cells under the "compassionate use protocol." The treatment with PLX, he reports, "has saved her life and can certainly be classified as a medical miracle."

Read about the seven-year-old girl with severe aplastic anemia who was saved with this treatment several months ago.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More